Revelation Biosciences grants CEO, CFO restricted stock awards of 208,076 shares each under 2021 equity plan

REVB•2026-08-19

Vesting conditions and acceleration triggers

The awards vest in four 25% tranches tied to market-cap thresholds of $30 million to $120 million over 20 consecutive trading days, or time-based dates.

Full vesting triggers on a change in control. Accelerated vesting also applies on death, termination without cause, or resignation for good reason.

Restricted stock awards granted to CEO and CFO

Revelation Biosciences granted restricted stock awards effective Aug. 17, 2026 to CEO James Rolke and CFO Chester S. Zygmont III.

Rolke received 208,076 shares.
Zygmont received 208,073 shares.

Sources

Revelation Biosciences grants CEO, CFO restricted stock awards of 208,076 shares each under 2021 equity plan

Sec

Revelation Biosciences grants CEO, CFO restricted stock awards of 208,076 shares each under 2021 equity plan

Vesting conditions and acceleration triggers

Restricted stock awards granted to CEO and CFO

Related News

AN2 Therapeutics director Robin Shane Readnour disposes of USD 212,486 common shares

NACCO subsidiary Coteau Properties receives MSHA imminent danger order at Freedom Mine

Synaptics VP, Corporate Controller Esther Song sells USD 44,109 of shares

Sources

Revelation Biosciences grants CEO, CFO restricted stock awards of 208,076 shares each under 2021 equity plan

Iceland's Alvotech H1 revenue falls 31% on manufacturing program

Solésence Q2 FY26 turns to net loss of $158,000; revenue falls 24.7% to $15.3 million